Exploratory Clinical Trial of Safety and Efficacy of Daily Application of Topical Dutasteride in Men With Androgenic Alopecia.

• Status: Recruiting
• Trial end date: 2024-04-29
• Target enrollment: 0
• Participant gender: Male

Summary

Alopecia is a disorder that involves the loss of hair from the body. The causes of hair loss can be multiple, but in all cases this loss causes a lot of discomfort to patients for aesthetic and psychological reasons, especially in the female population.This study is going to focus on the topical use of dutasteride in the treatment of men with androgenic alopecia using a new formulation, as an emulsion, capable of transporting this drug to the different structures of the pilosebaceous unit.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
• Treatments: Dutasteride

Criteria

Inclusion Criteria:

• • - Males over 18 years of age, diagnosed with Sinclair grades I-IV androgenic alopecia, who are not currently undergoing any hair treatment and have not undergone any in the last 3 months.

• - Understand the purpose of the study and be available for frequent visits to the hospital. Sign the informed consent form.

• - Males with a partner of childbearing age must agree to use a contraceptive method with the partner for the duration of the study.

Exclusion Criteria:

• • - Patients with a history of hypersensitivity to the active ingredient, to other 5-alpha reductase inhibitors.

• - Patients with severe hepatic insufficiency.

• - Patients who are currently undergoing capillary treatment or have undergone capillary treatment in the last 3 months.

• - Patients unable to understand the objective of the study or to give informed consent.

• - Patients who, in the opinion of the investigator, present any difficulty or situation that would hinder or contraindicate their participation in this study.

• - Patients with a history of drug addiction and drug addictions.

• - Patients who are participating in another clinical trial.

• - Patients whose partner is pregnant